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Chronic feeding of 1-O~ctadecyl-sn-glycerol (batyl alco- 
hol) to patients suffering from congenital deficiency in 
tissue ether glycerolipids showed an increase in the plas- 
malogens content of their erythrocytes. However, nothing 
is known about the ether lipid content of other tissues 
in these patients. Feeding 1-O-heptadecyl-sn-glycerol to 
young rats showed that this uncommon ether lipid was 
incorporated to a high extent into the plasmalogens of 
all tissues except brain. Comparative studies with other 
precursors, such as 3~O-heptadecyl-sn-glycerol, hepta- 
decanol and heptadecanoic acid, indicated a stereospecific 
incorporation of the dietary 1-O-alkTl-sn-glycerols into 
tissue plasmalogens without cleavage of the ether bond. 
Dietary ether lipids were also shown to be transferred 
from mothers to suckling rats, but not from pregnant rats 
to fetuses. The implication of these results to possible 
dietary ether Hpid therapy for patients suffering from 
peroxisomal disorders is discussed. 
Lipids 27, 401-405 (1992). 
In mammals, 1-O-alkyl-sn-glycerols derived from dietary 
ether glycerolipids are absorbed without cleavage of the 
ether bond (1). This was first shown by Bergstr6m and 
Blomstrand (2) who fed radioactive 1-0-[1'-14C]hexadecyl- 
rac-glycerol (chimyl alcohol) to rats and showed that it was 
completely absorbed by the intestine About half of the 
radioactive lipids recovered from the lymphatic fluid were 
shown to be either chimyl alcohol or its esterified 
derivatives, and the rest of the radioactivity was recovered 
in palmitic acid. Using human subjects, a similar finding 
was reported by Blomstrand and Ahrens (3). Apparently 
after absorption, all of the unnatural isomer (sn-3-alkyl) 
and part of the natural (sn-l-alkyl) isomer were oxidized 
in the intestinal mucosal cells to form palmitic acid (4). 
This was demonstrated later by Paltauf (5) who admin- 
istered labeled natural (1-O-hexadecyl-sn-glycerol) and un- 
natural (3-O-hexadecyl-sn-glycerol) glycerol ether isomers 
to rats and showed that only the natural isomer was incor- 
porated into intestinal mucosal lipids. Paltauf also showed 
that the exogenous alkylglycerol was further metabolized 
to plasmalogens in intestinal mucosal cells (5). Mangold 
(1) and Bandi et  aL (6) reported similar findings by feeding 
rats glycerol ethers which contained unnatural (18:2, 18:3) 
alkyl chains. These works have found that dietary ether 
glycerolipids are not only incorporated into membrane 
ether lipids of intestinal mucosal cells, but a small 
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portion is also transported to liver and incorporated into 
plasmalogens in that tissue (6). Reichwald and Mangold 
(7) fed rats 1-alkyl glycerols having unnatural, odd-num- 
bered and polyunsaturated alkyl groups (13:0, 15:0, 17:0, 
19:0, 19:1 and 19:2) and studied their incorporation into 
lipids of intestinal mucosal cells. They found that al- 
though all of these glycerol ethers are incorporated into 
alkylacyl-glycerophosphoethanolamine (GPE) and alkyl- 
acyl-glycerophosphocholine (GPC), only the glycerol 
ethers containing 17:0, 19:0 and 19:1 chain lengths are con- 
vetted into the corresponding ethanolamine and choline 
plasmalogens. Weber (8) showed that dietary 1-O-dodecyl- 
rac-glycerol is incorporated into the alkylglycerolipids, but 
not into the plasmalogens, of all tissues in mice 
These studies from different laboratories established 
that mammals can utilize dietary glycerol ethers to make 
membrane ether lipids in different tissues. In recent years, 
the possible incorporation of exogenous ether lipids into 
tissue plasmalogens has assumed clinical significance 
because of the discovery of a number of genetic diseases 
involving ether lipid deficiency (9-11). 
Heymans et  aL (12) first reported the almost complete 
absence of ether lipids in the tissues of patients suffer- 
ing from Zenweger cerebrohepatorenal syndrome This 
deficiency of ether lipids is due to the absence of perox- 
isomes in the tissues of these patients (13). Peroxisomes 
have been shown to be the site for synthesis of ether lipids 
(14). It has been demonstrated that the activity of di- 
hydroxyacetone phosphate acyltransferase (DHAPAT), 
which catalyzes the biosynthesis of the precursor of ether 
lipids, acyl dihydroxyacetone phosphate (acyl DHAP) 
(Fig. 1), is very low in the tissues of Zellweger patients 
(15-17). The activity of the enzyme catalyzing the syn- 
thesis of the ether bond, i.e., alkyl DHAP synthase 
(Fig. 1), is also somewhat low in these patients (15,17,18). 
The deficiency of these peroxisomal enzymes, required for 
the de novo biosynthesis of the ether bond in ether 
glycerolipids, results in a decreased amount of 
plasmalogens in the tissues of Zellweger patients. The 
same enzymes have also been shown to be deficient in a 
number of other genetic diseases involving peroxisomal 
disorders, such as neonatal adrenoleukodystrophy (19), in- 
fantile Refsum disease (20), rhizomelic chrondrodysplasia 
punctata (9) and others {21). On the other hand, the ac- 
tivity of the key enzyme necessary for the utilization of 
exogenous 1-O-alkyl-sn-glycerol, i.a, alkyl glycerol kinase 
(Fig. 1), was shown not to be deficient in these patients 
(15). Considering that the enzymes that catalyze the con- 
version of 1-alkyl-sn-glycerol-3-phosphate to membrane 
ether glycerolipids and plasmalogens are localized not in 
peroxisomes (14,22) but in the endoplasmic reticulum (Fig. 
1), it is expected that exogenous alkyl glycerols might be 
incorporated into tissue ether lipids in these patients. This 
has been shown to be the case in cultured skin fibroblasts 
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FIG. 1. Subcelludar compartmentation of the enzymatic reactions 
leading to the biosynthesis of alkyl glycerol ethers and plasmalogens. 
obtained from Zellweger patients where the labeled alkyl 
glycerols, added to the culture medium, are incorporated 
into cellular plasmalogens, but the labeled long-chain 
alcohols are not {23,24). 
ORAL ETHER LIPID THERAPY IN PATIENTS 
WITH ETHER LIPID DEFICIENCY 
The findings snmmarized above led us to hypothesize that 
oral administration of ether lipids to patients with perox- 
isomal disorders might rectify the tissue ether lipid defi- 
ciency {15,25). Our group has given several patients with 
peroxisomal disorders an ether lipid suspension contain- 
ing 400 mg 1-O-octadecyl-sn-glycerol (batyl alcohol) and 
200 mg sodium deoxycholate in 100 mL of water. Each 
patient received 5-10 mg/kg daily of batyl alcohol {25). 
Case histories for three patients are described below. 
Patient 1. NR was born on May 26, 1983, following a 
full-term gestatiorL Birth weight was 3.13 kg {50%), length 
54 cm (95%) and head circumference 34.5 cm {50%). He 
was evaluated at 7 weeks of age because of failure to thrive 
and was noted to have hypotonia and enlarged anterior 
and posterior fontanels with diastasis of the sagittal 
suture Hepatomegaly was present at age 4 months and 
serum aminotransferase levels were elevated. Per- 
cutaneous liver biopsy showed abnormal lobuiar architec- 
ture with fibrous septa extending from portal tracts 
into the surrounding parenchym& By 8 months of age he 
could not visually fix on objects and had wandering 
nystagmus. Ophthalmologic evaluation revealed bilateral 
punctate cortical and plaque-like nuclear changes, optic 
atrophy and retinal degeneration. 
A skin biopsy was performed at 1 year of age and 
fibroblasts were cultured, harvested and assayed for the 
activity of the peroxisomal membrane enzyme, dihydroxy- 
acetone phosphate acyltransferase (DHAPAT). The activ- 
ity was 30% of control. Plasma levels of C26 very long- 
chain fatty acids and the ratio of C2JC22 assayed at 20 
months of age were elevated in a pattern diagnostic of 
neonatal adrenoleukodys trophy. 
Dietary supplementation with batyl alcohol was started 
in August, 1984, and continued through May, 1987. The 
child is currently enrolled in special education classes with 
a level of development equivalent to a young toddler. He 
has not yet developed clinical or laboratory evidence of 
adrenal insufficiency {normal cortrosyn stimulation test 
at age 8 1/2 years). 
Patient 2. EZ was born at 40 weeks gestation by emer- 
gency cesarean section on September 28, 1982, because 
of fetal distress and maternal hypertension. Birth weight 
was 2.5 kg and length 53 cm. At 6 months of age she was 
evaluated for failure to thrive, hypotonia and hepato- 
megaly. A liver biopsy was performed and sections of the 
liver showed bridging fibrosis and paucity of intrahepatic 
bile ducts without cholestasis. 
She was re-evaluated at age 2 years because of failure 
to thrive, delayed development, seizures, hypotonia and 
persistent hepatomegaly with elevated levels of serum 
amlnotransferases. Her facies was not dysmorphic, al- 
though there was a high-arched palat~ Because of these 
findings, fibroblasts cultured from a skin biopsy were 
assayed for DHAPAT. The activity of fibroblast DHAPAT 
was 0.125 nmol/min/mg protein (control value = 0.2 nmol/ 
rain/rag protein). The reference non-peroxisomal enzyme 
glycerol-3-phosphate acyltransferase had values of 0.89 
nmol/min/mg {control = 0.81 nmol/min/mg protein). 
Erythrocyte plasmalogen content was assayed at age 3 
years and was abnormal (Table 1). 
She was given a suspension of batyl alcohol from July, 
1985, until February, 1989. There were no adverse effects. 
TABLE 1 
Erythrocyte Ethanolamine Plasmalogen Concentration Before 
and After Administration of Batyl Alcohol a 
Ethanolamine plasmalogen 
(% of total phospholipids) 
Patient Patient Patient 
no. I no. 2 no. 3 
Pretreatment value 4.0 1.3 4.1 
Post-treatment value 10.6 1 i. 2 7.5 
aErythrocyte phospholipid composition was analyzed by two-dimen- 
sional thin-layer chromatography as previously described (30). The 
percentage of ethanolamine plasmalogen is shown here. Most of 
the other phospholipid percentages were the same as normal ex- 
cept for phosphatidylethanolamine, which was increased. The 
ethanolRmine plasmalogen contents of normal subjects varies from 
10% to 15% of the total phospholipids. For further details, see text 
and ref. 25. 
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She is presently attending a school for developmentally 
handicapped children and is beginning to wall~ There is 
marked speech delay. 
Pat ien t  3. CB was born on January 14, 1986, following 
full-term gestation. Hypotonla and strabisimus were pres- 
ent at birth. He was evaluated at age 4 months because 
of failure to thrive, and was noted to have a dysmorphic 
facies and hepatomegaly. Plasma very long chain fatty 
acid levels were elevated and the activity of fibroblast 
DHAPAT was determined to be 40% of control value 
These findings supported the diagnosis of neonatal 
adrenoleukodystrophy. 
A cortrysn stimulation test was performed in March, 
1988. The result was abnormal and hydrocortisone re- 
placement therapy was startecL In October, 1988, he devel- 
oped a diffuse, erythematous skin rash, associated with 
elevation of plasma phytanic acid. 
An oral suspension of batyl alcohol was prescribed in 
October, 1986, and continued to January, 1989. The eryth- 
rocyte plasmalogen content was measured before and after 
treatment with batyl alcohol. The results are summarized 
in Table 1. 
At the present time, he is attending a special education 
program for hearing-impaired and vision-impaired 
children. He has marked developmental delay and is not 
yet able to walk. 
The results presented in Table 1 show that erythrocyte 
plasmalogen levels are increased in these patients after 
oral feeding of batyl alcohol for a few months. In one pa- 
tient, who was under oral batyl alcohol therapy for three 
months, the chain length distribution of the alk-l'-enyl 
moiety of ethanolamine plasmalogens from erythrocytes 
was analyzecL An increase in the 18:0 moiety (68% vs. 50% 
in normal controls) was observed, suggesting that the 
dietary batyl alcohol was absorbed, metabolized and in- 
corporated into the erythrocyte plasmalogens of this 
patient. 
Administration of oral ether lipids represents a poten- 
tial treatment for patients with peroxisomal disorders. 
Although none of the patients reported in this series have 
the severe Zellweger phenotype associated with multiple 
peroxisomal enzyme deficiency, they all share clinical 
features typically seen in patients with peroxisomal dys- 
function: failure to thrive, delayed development, hypo- 
tonia, facial dysmorphia and hepatomegaly. Each of these 
patients has a documented defect of plasmalogen syn- 
thesis and oxidation of fatty acids. These infants have ex- 
hibited subjective improvement of nutritional s tatus  liver 
function, retinal pigmentation and motor tone and reple- 
tion of deficient red cell ethanolamlne plasmalogens since 
receiving batyl alcohol. However, it is not possible to sepa- 
rate these changes from the natural history of untreated 
disease Wanders et  aL {26) have documented increasing 
plasmalogen levels in Zellweger's syndrome as a function 
of age. This may be due to the intake of natural alkylglyc- 
erols present in foocL Horrocks (27) estimated that the ave~ 
age adult consumes 10-100 mg of batyl alcohol each day. 
INCORPORATION OF DIETARY ALKYLGLYCEROL 
INTO PLASMALOGENS OF DIFFERENT TISSUES 
IN RATS 
The increase in the plasmalogen level in erythrocytes of 
patients after feeding batyl alcohol indicated that dietary 
ether lipids may also be incorporated into different tissues 
of these patients. However, a direct demonstration of such 
an increase in tissues of these patients was not feasible 
There are also no reports of incorporation of dietary ether 
lipids into plasmalogens of different tissues of animals ex- 
cept in intestinal mucosa (1,5) and, to a small extent, in 
liver of rats (6). By contrast, there are reports of nouin- 
corporation of exogenous tracer doses of labeled ether 
lipids into tissue plasmalogens of animals (28,29). There- 
fore, to determine whether dietary ether lipids are utilized 
to synthesize membrane ether lipids of different tissues, 
we administered 1-C~heptadecyl-sn-glycerol to young rats. 
The odd chain heptadecyl moiety is practically absent in 
normal ether glycerolipids, but it is very sJmilar to the 
alkyl and alk-l'~nyl groups of tissue lipids that are mainly 
composed of 16:0, 18:0 and 18:1 chains. By feeding rats 
(19-d-old) 1-O-heptadecyl-rac-glycerol (1-2% mixed with 
food) for 5 to 10 days, we found a very high (46-60%) in- 
corporation of the C17-moiety at the C-1 position of etha- 
nolamine plasmalogens in most tissues of these rats (30). 
However, the total plasmalogen content of the tissues did 
not increas~ These results show that dietary alkyl glycerol 
ethers are not only absorbed and converted to 
plasmalogens in intestinal tissue, but are also transported 
to other organs where they are metabolized and deposited 
as membrane plasmalogens. The incorporation of the ex- 
ogenous ether lipids into tissue plasmalogens is quite 
high, much higher than reported previously (7). This is 
probably due to our use of young growing rats for these 
experiments, as opposed to the use of adult rats by other 
authors. Recently, Blank et  al. (31) reported a similar 
observation. These authors fed 1-O-alkyl-2,3-diacetyl-sn- 
glycerol, containing 65% 18:1 and 17% 16:1 alkyl groups, 
to rats, and found an increase in the 18:1 group of alkyl 
and alk-l'-enyl side chains of ether phosphoglycerides in 
liver, kidney and lung. There was an increase in the alkyl 
glycerol ether content but, as we have found, no change 
in the plasmalogens content of these tissues (31). We ftm 
ther investigated the mode of incorporation of dietary 
ether lipids into tissue lipids by feeding different precur- 
sors of ether lipids, such as heptadecanoic acid, hep- 
tadecanol, 1-O-heptadecyl-sn-glycerol and 3-O-heptadecyl- 
sn-glycerol, to young rats. The results are summarized in 
Figure 2. It is seen that 1-O-heptadecyl-sn-glycerol is the 
best precursor, whereas its unnatural optical isomer, 3-O- 
heptadecyl-sn-glyceroL is incorporated only to a very small 
extent. Apparently, the sn-3 isomer is oxidized to hep- 
tadecanoic acid (the mono-oxygenase oxidizing the ether 
bond is non-stereospecific, see ref. 32) which is further 
utilized. This conclusion is supported by the higher 
percentage of incorporation of heptadecanol and hep- 
tadecanoic acid than of the sn-3 isomer (Fig. 2). The 
relative incorporation rates, i.e 1-O~heptadecyl-sn-glycerol 
>> heptadecanol > heptadecanoic acid > 3-O-heptadecyl- 
sn-glycerol {Fig. 2), suggest that the pathway shown 
{Fig. 1) for the incorporation of different precursors into 
ether lipids is operative in all tissues. These results and 
results from other laboratories {7,8,31) indicate that most 
exogenous long chain ether lipids incorporate into 
alkylglycerol ether lipids, but the subsequent conversion 
to plasmalogens occurs only in lipids containing alkyl 
chain lengths between C,s and C19 {saturated or monoun- 
saturated). Thus, it appears that, physiologically, the 
l'-alkenyl chain lengths are restricted to a narrow range, 
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FIG. 2. Incorporation of dietary l-O-heptadecyl-sn-glycerol, hep- 
tadecanol, heptadecanoic acid and 3-O-heptadeeyl-sn-glycerol into 
ethanolamine plesmalogen of the tissues of 19-dny~ld rats. Rats were 
fed either powdered food mixed with the indicated compounds (1%, 
w/w) or only the powdered food alone (control group) for 5 days, and 
then the chain length distributions of the alk-l'~nyl group at C-I 
position of ethanolsmine plasmalogen of liver, kidney and hrain were 
analyzed, as described previously (30). 
not only by the specificity of the acyl-CoA reductase (33), 
but also by the chain length specificity of the dehydro- 
genase which converts 1-O-alkyl phosphoglycerides to 1-(~ 
[l'alkenyl]phosphoglycerides (34}. The nature of the ether 
lipids transported from intestine to liver or to other organs 
is a matter of speculation. However, it is plausible that 
esterified alkylglycerols {ether analogs of triglycerides} are 
transported from the intestine {2-4} and liver to other 
organs and that these alkylglycerol derivatives are utilized 
after partial or complete hydrolysis of the ester bonds. 
Neutral lipids, whose chromatographic migration rate is 
similar to alkyldiacylglycerol, were found to be present 
in the liver and kidney of animals who were chronically 
fed heptadecylglycerol (Das, A.K., and Hajra, A.K., un- 
published observation; see also ref. 31). 
The results of our animal feeding experiment show that 
dietary ether glycerolipids are effectively utilized to syn- 
thesize membrane ether lipids in most tissues. However, 
in brain the incorporation of the exogenous ether lipid 
precursor was always very low (ref. 30 and Fig. 2). This 
could possibly be due to either a low rate of ether lipid 
synthesis in brain after myelination is complete, or to the 
fact that the ether lipid precursors cannot cross the blood- 
brain barrier. To resolve this question, ether lipids should 
be fed to rats before the start of myelination (<10 d old}. 
It  is difficult, however, to feed large amounts of ether 
lipids to these suckling rats. Therefore" we fed pregnant 
female rats powdered food containing 0.5% (w/w} 1-O- 
heptadecyl-sn-glycerol on the fifth day before delivery, and 
continued until the fourteenth day after the pups were 
born. The babies were allowed to suck the mother's milk 
which, when analyzed, was found to contain 1-O-alkyl- 
2,3-diacyl-sn-glycerols. When the tissues of the babies 
(14-d-old) were analyzed, 28% of liver and 17% of kidney 
alk-l'~nyl groups of ethanolamine plasmalogen were found 
to contain the 17:0 moiety. These values were lower than 
those obtained by direct feeding of heptadecylglycerol (30). 
In brain, a low (2%) incorporation of 17:0 in the alkenyl 
chain was also observec~ It is not clear whether this low 
incorporation into brain lipid is due to the blood-brain ba~ 
rier or to the lower consumption of heptadecylglycerol by 
the babies. In another experiment, we found no incorpora- 
tion of the 17:0 moiety in the tissues of newborn babies 
whose mothers had been fed 1-(~heptadecylglycerol for 20 
days during pregnancy, though the mothers' tissues con- 
tained a high percentage (40-60%) of the heptadec-l'-enyl 
moiety in the ethanolamine plasmalogens. This indicates 
that ether lipids are not transported across the placenta 
from mother to fetus. 
From these results it is evident that dietary ether lipids 
can be directly utilized by mammals to synthesize mem- 
brane alkyl glycerolipids and plasmalogens in most 
tissues. Although the utilization of the exogenous ether 
lipids for the formation of brain plasmalogens is some- 
what questionable, there was a low but reproducible in- 
corporation of 1-O-heptadecyl-sn-glycerol into brain ether 
lipids (ref. 30, Fig. 2). It  is possible that the exogenous 
ether lipids would be more effectively utilized if there were 
no endogenous formation of ether lipids. Increasing the 
dose might result in higher incorporation of ether lipids 
in all tissues of the patients. Oral ether lipid therapy may 
never relieve all of the syndrome associated with these 
diseases because of multiple peroxisomal enzyme defects 
{10,22). But, in mild cases, where the main problem is the 
deficiency of ether lipids, oral ether lipid therapy may 
prove helpful. Alkyl glycerols are fairly innocuous com- 
pounds which have been shown to be nontoxic even at high 
doses (1}, and no harmful effects are expected when these 
compounds are chronically administered to the patients. 
Oral ether lipid therapy should be attempted to alleviate 
some of the symptoms associated with these peroxisomal 
disorders. 
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